468 related articles for article (PubMed ID: 22678158)
1. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
[TBL] [Abstract][Full Text] [Related]
2. Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center.
Murthy SS; Sandhya DG; Ahmed F; Goud KI; Dayal M; Suseela K; Rajappa SJ
Indian J Pathol Microbiol; 2011; 54(3):532-8. PubMed ID: 21934215
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival.
Kakar S; Puangsuvan N; Stevens JM; Serenas R; Mangan G; Sahai S; Mihalov ML
Mol Diagn; 2000 Sep; 5(3):199-207. PubMed ID: 11070154
[TBL] [Abstract][Full Text] [Related]
4. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
5. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
[TBL] [Abstract][Full Text] [Related]
6. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification.
Lal P; Salazar PA; Ladanyi M; Chen B
J Mol Diagn; 2003 Aug; 5(3):155-9. PubMed ID: 12876205
[TBL] [Abstract][Full Text] [Related]
7. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
8. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
[TBL] [Abstract][Full Text] [Related]
9. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach.
Ridolfi RL; Jamehdor MR; Arber JM
Mod Pathol; 2000 Aug; 13(8):866-73. PubMed ID: 10955453
[TBL] [Abstract][Full Text] [Related]
10. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
11. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice.
Ma Y; Lespagnard L; Durbecq V; Paesmans M; Desmedt C; Gomez-Galdon M; Veys I; Cardoso F; Sotiriou C; Di Leo A; Piccart MJ; Larsimont D
Clin Cancer Res; 2005 Jun; 11(12):4393-9. PubMed ID: 15958623
[TBL] [Abstract][Full Text] [Related]
12. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
[TBL] [Abstract][Full Text] [Related]
13. Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.
Prati R; Apple SK; He J; Gornbein JA; Chang HR
Breast J; 2005; 11(6):433-9. PubMed ID: 16297088
[TBL] [Abstract][Full Text] [Related]
14. Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast.
Boulos F; Farra CG; Saad Aldin EM; Masaad C; Hassoun Y; Fedda F; Doumiati H; Tawil AN; Nasser Z; Nahleh Z; Tfayli A
J Clin Pathol; 2014 Mar; 67(3):204-9. PubMed ID: 24108431
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.
Kokate P; Sawaimoon S; Bhatia S; Mandava S
Genet Test Mol Biomarkers; 2012 Apr; 16(4):239-45. PubMed ID: 22023243
[TBL] [Abstract][Full Text] [Related]
16. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
17. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics].
Li HH; Ma F; Zeng X; Wang JY; Yuan P; Fan Y; Xu BH
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(2):76-80. PubMed ID: 21418986
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
